Brooks Laboratories
66.05
+1.69(+2.63%)
Market Cap₹194.57 Cr
PE Ratio8.84
IndustryHealthcare
Company Performance:
1D+2.63%
1M+43.49%
6M-45.69%
1Y-53.04%
5Y-15.64%
View Company Insightsright
More news about Brooks Laboratories
12Nov 25
Brooks Laboratories Receives Credit Rating Upgrade, Reflecting Improved Financial Outlook
CARE Ratings upgraded Brooks Laboratories Limited's (BLL) long-term bank facilities rating to 'CARE BB; Stable' from 'CARE BB-; Stable', while reaffirming its short-term rating at 'CARE A4'. The upgrade is based on expected financial performance improvements and benefits from a merger involving its associate company. BLL projects a total operating income of ~₹100 crore in FY26 with improved profit margins. The merger of BLL's associate, Brooks Steriscience Limited, into OneSource Speciality Pharma Limited is expected to enhance BLL's liquidity and financial risk profile.
 no imag found
26Sept 25
Brooks Steriscience Approves Multi-Entity Merger Scheme to Consolidate Sterile Injectable Operations
Brooks Steriscience Limited, a subsidiary of Brooks Laboratories, has approved a significant corporate restructuring plan involving a composite scheme of arrangement and amalgamation of five pharmaceutical entities. The merger aims to consolidate sterile injectable manufacturing operations under OneSource Specialty Pharma Limited. The scheme involves Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte Limited, Strides Pharma Services Private Limited, and OneSource Specialty Pharma Limited. Share exchange ratios have been set, with post-merger promoter shareholding in OneSource expected to increase to 36.17%. The consolidation is designed to strengthen CDMO capabilities, create operational synergies, and enhance shareholder value. The scheme requires approvals from various regulatory authorities.
 no imag found
13Aug 25
Brooks Laboratories Reports Robust Q1 FY26 Results with 265.06 Lakh Net Profit
Brooks Laboratories Limited announced impressive Q1 FY26 results, posting a net profit of Rs. 265.06 lakhs compared to a loss in the previous year. Revenue surged 42.3% to Rs. 2,551.19 lakhs. Consolidated performance was even stronger with a net profit of Rs. 958.48 lakhs, boosted by its joint venture Brooks Steriscience Limited. The company's Basic EPS improved to Rs. 0.90 from negative Rs. 0.08 year-over-year.
 no imag found
Brooks Laboratories
66.05
+1.69
(+2.63%)
1 Year Returns:-53.04%
Industry Peers
Sun Pharmaceutical
1,624.90
(-3.29%)
Divis Laboratories
6,373.00
(-0.09%)
Torrent Pharmaceuticals
4,099.30
(-1.15%)
Dr Reddys Laboratories
1,308.90
(-1.66%)
Lupin
2,309.20
(-1.38%)
Cipla
1,289.20
(-1.28%)
Mankind Pharma
2,281.00
(-0.52%)
Zydus Life Science
926.30
(-2.12%)
Aurobindo Pharma
1,428.90
(-0.45%)
Alkem Laboratories
5,516.50
(-0.07%)